The FDA has launched the Commissioner’s National Priority Voucher (CNPV) pilot program to grant accelerated review times of one to two months for new drugs aligning with U.S. national health priorities. The program priorities include onshoring drug development, increasing affordability, treating rare diseases, addressing public health crises, and chronic disease management. The agency provided examples of eligible products, such as universal flu vaccines and treatments that maintain robust U.S. clinical trial enrollment, intending to strengthen drug access and supply chain resilience.